What ChondroFiller actually does inside a joint

When ChondroFiller® is introduced into a joint, it does not simply coat or lubricate the surface. Within minutes of contact with body temperature, the purified Type I collagen solution polymerises into a soft three-dimensional scaffold that sits directly over the cartilage defect — acting less like a filler and more like a temporary biological invitation.

That invitation is to the body's own cells. The scaffold creates a chemotactic environment that draws mesenchymal progenitor cells in from the surrounding synovium and subchondral bone — a process the literature describes as acellular matrix-induced chondrogenesis (ACIC). Crucially, ChondroFiller carries no living cells, growth factors, or pharmaceutical agents; it is entirely acellular, classified as a CE-marked Class III medical device rather than a drug or cell therapy. Evidence suggests that host cells migrate into the scaffold and begin laying down repair tissue: an ex vivo osteochondral explant study recorded a 2.4-fold increase in DNA content within the scaffold by day 14, indicating rapid cell infiltration — though this is laboratory-based evidence rather than a direct clinical outcome measure.

Over roughly three to six months, the collagen matrix gradually resorbs as the patient's own fibrocartilage-like repair tissue matures in its place.

This mechanism sets ChondroFiller apart from hyaluronic acid, which lubricates the joint but does not scaffold new tissue, and from hydrogel cushioning products, which occupy space without attempting to restore structural integrity.

Why the hip makes injection more technically demanding

Anatomy explains why placing anything accurately inside the hip is meaningfully more involved than an equivalent injection into the knee or shoulder. The hip is the deepest ball-and-socket joint in the body, wrapped on all sides by thick layers of muscle; the anterior joint capsule recess — the practical target for ChondroFiller placement — sits 6–10 cm beneath the skin surface in most adults.

Running across the anterior approach path are the femoral artery and vein. Their presence is the principal reason colour Doppler mapping is performed before the needle is advanced: the vessel positions are confirmed, and the needle trajectory is planned to pass safely lateral to them. Under real-time ultrasound guidance this is a routine step, not a hazard.

Two pieces of specialist equipment follow from these anatomical realities. First, the standard high-frequency linear transducer adequate for superficial joints cannot penetrate to the hip capsule with sufficient image clarity; a low-frequency curved-array probe is required instead. Second, the needle must be long enough to traverse skin, subcutaneous fat, anterior hip musculature, and the iliofemoral ligament — typically an 85–100 mm spinal or echogenic needle rather than the shorter gauge used at shallower sites.

Taken together, these factors make ultrasound guidance essential rather than optional. With it, real-time visualisation converts anatomical complexity into a manageable, image-controlled outpatient procedure.

How the procedure works, step by step

The appointment takes place in an outpatient clinic under local anaesthesia, typically lasting under an hour from preparation to discharge.

The patient is positioned supine on the treatment couch with the hip in slight external rotation — a small adjustment that flattens the anterior joint capsule against the femoral neck and meaningfully improves the ultrasound image for the clinician.

Before any needle is placed, the clinician positions the curved-array transducer in a longitudinal-oblique plane over the anterior hip, aligned to the femoral neck axis. This orientation brings the femoral head, femoral neck, and anterior joint capsule into a single view simultaneously. Colour Doppler imaging is then activated to confirm the positions of the femoral artery and vein, and the needle path is planned to pass lateral to both structures.

With the vascular anatomy mapped, a long spinal needle is introduced from the lateral and inferior edge of the transducer, kept strictly in-plane so the shaft remains fully visible throughout. The clinician tracks the tip in real time as it advances through skin, subcutaneous fat, and the iliofemoral ligament. When the tip makes gentle contact with the cortex of the femoral neck, it is withdrawn a few millimetres, repositioning it in the anterior capsule recess — the correct intra-articular target.

ChondroFiller is then injected slowly. Correct placement is confirmed visually on screen: the anterior joint capsule distends as the scaffold fills the recess. Because the injectable formulation is designed to polymerise and adhere in a fluid joint environment, no draining or drying of the joint space is needed beforehand — which is precisely what makes this a clinic appointment rather than a theatre procedure.

Which hip problems tend to be most suitable

Published arthroscopic cohort data point to an isolated, full-thickness acetabular cartilage defect of roughly 2–6 cm², contained within healthy surrounding cartilage borders, as the consensus sweet spot for ChondroFiller in the hip. Defects at the smaller end of that range, with well-defined edges and no widespread joint thinning, tend to present the most straightforward case for this approach.

The most commonly described clinical context in the literature is cam-type femoroacetabular impingement (FAI) producing anterosuperior acetabular lesions in younger, active patients. This pattern — a mechanical conflict at the hip that damages cartilage in a relatively contained zone — aligns closely with what ChondroFiller is designed to address.

Where advanced osteoarthritis is already present, the picture changes. Published arthroscopic series (including Mazek 2021, Journal of Hip Preservation Surgery) indicate that patients with Tönnis grade 2–3 pre-existing joint degeneration have not fared as well; outcome data for this group are covered in more detail later. The injectable route may extend eligibility modestly by providing a top-down cushion over worn surfaces rather than requiring a pristine defect bed, but expectations should be adjusted accordingly and assessed on an individual basis.

Widespread joint degeneration, inflammatory arthritis, or very large and poorly bordered defects are generally considered less suitable for this approach.

Because suitability depends on imaging findings, defect characteristics, and overall joint health, a formal clinical assessment is the appropriate next step — not self-selection based on symptom description alone. Find out if you may be suitable.

Recovery and what to expect in the weeks after

Load management in the days and weeks after injection is more consequential here than for a routine joint injection. Biomechanical data confirm that the collagen gel begins in a soft, malleable state: under the forces of full weight-bearing it can be displaced before it has stabilised within the defect. A period of reduced loading — commonly a matter of weeks, with the exact duration determined by the treating clinician according to defect characteristics and individual factors — is therefore standard before a graduated return to activity begins.

Physiotherapy-guided loading through the return phase matters too. Controlled, progressively increased movement encourages the cell infiltration and matrix remodelling the scaffold is designed to support; unguided early return to strenuous activity risks undermining both.

The underlying biological process takes considerably longer. Over approximately three to six months, the collagen scaffold resorbs as the patient's own repair tissue gradually matures — this is an approximate biological window, not a fixed schedule, and the pace varies between individuals. Symptom improvement tends to follow a gradual arc across this period rather than arriving immediately after the appointment.

Not everyone responds identically. Some patients report progressive easing of symptoms over the resorption period; others experience a slower or more modest change and may benefit from reassessment to consider whether the broader treatment plan needs adjustment. The quality of the repair tissue that eventually forms also depends partly on how precisely the scaffold was delivered: excess volume within the defect is a documented risk that may skew the outcome towards fibrous rather than cartilage-like tissue — a factor that is as relevant to the long-term result as it is to the moment of injection itself.

What the evidence shows — and where gaps remain

The most robust hip-specific data to date come from Mazek (2021, Journal of Hip Preservation Surgery), a prospective cohort of 26 adults treated with ChondroFiller gel during hip arthroscopy: 17 of 21 evaluable patients reached good or excellent outcomes at three to five years of follow-up. Two caveats matter when reading that result in the context of ultrasound-guided injection. First, delivery was arthroscopic, not injectable — meaning the clinical setting, joint preparation, and gel placement differ meaningfully from the outpatient approach. Second, n=26 is a modest cohort; larger, controlled studies represent the logical next step.

Perez-Carro (2021) provides additional support for the injectable route specifically, reporting favourable findings when injectable ChondroFiller was used for full-thickness acetabular defects. That gives the outpatient pathway an evidence anchor beyond simple extrapolation from arthroscopic series.

Across the broader ChondroFiller evidence base, randomised controlled trial data are predominantly drawn from knee populations. Extrapolation to the hip is clinically reasonable — the scaffold mechanism does not depend on which joint receives it — but a hip-specific randomised trial has not yet been completed. Equally, no published study has placed ultrasound-guided hip injection directly alongside arthroscopic delivery in a comparative design; the injection route rests on arthroscopic outcome data combined with the well-established ultrasound technique already used routinely for other injectates in hip practice.

These gaps reflect an active area of clinical development rather than a fundamental question mark over the approach. Whether the current evidence supports treatment for a specific individual depends on imaging findings and defect characteristics — factors that a formal clinical assessment is best placed to weigh.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Controlled, randomized multicenter study comparing ChondroFiller liquid with microfracturing in focal knee cartilage defects. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
3. [3] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
4. [4] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z